Nonmyeloablative (NMA) hematopoietic stem cell transplantation for renal cell carcinoma (RCC)
Record ID 32010000942
English
Authors' objectives:
Renal cell carcinoma (RCC) is the most common primary renal cancer in adults. More than 25% of patients have metastatic disease at the time of diagnosis. Their prognosis is extremely poor, with a median survival of 10 to 15 months, and a 5-year survival rate of less than 10%. Immunotherapy with interleukin-2 or interferon-alfa is considered usual care in advanced RCC. However, response rates are low for these immune-based treatments, and there are tolerability issues. Therefore, other types of immunotherapy are being investigated.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=4084
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Carcinoma, Renal Cell
- Transplantation, Homologous
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.